What’s New in the Medicine Chest: Psoriasis

In a recent interview with Dermatology Times, James Del Rosso, DO, a dermatologist based in Las Vegas, Nevada, shared insights on recent advances in the treatment of palmoplantar pustulosis and psoriasis that he presented in a talk titled, “What’s New in the Medicine Chest?” at Winter Clinical Miami. As a clinician who also runs a research center and participates in educational programs, Del Rosso emphasized the importance of innovative therapies for these challenging conditions.

One notable case was highlighted from theJournal of Dermatology Physician Assistance. David Altman, MD, a respected Michigan-based clinician and researcher, documented a patient with palmoplantar pustulosis successfully treated with a topical cream, roflumilast “The topical roflumilast cream worked very, very well in a patient with pustulosis on the plantar area,” Del Rosso explained. He noted photographs accompanying the report demonstrated significant improvement.

Del Rosso also shared a case from his colleague, Jason Mammino, DO, of Advanced Dermatology and Cosmetic Surgery. The patient, an adult with psoriasis affecting various areas, experienced severe plantar involvement, including cracks, fissures, and difficulty walking. Treatment involved the injectable medication bimekizumab, approved for psoriasis at a standard dose of 320 mg subcutaneously. “After the first 2 doses, he had complete clearance of very extensive and very painful plantar psoriasis,” noted Del Rosso. This rapid and impressive response also extended to other affected areas, such as the hands and nails.These cases underscore the evolving therapeutic landscape for severe dermatologic conditions, offering hope for improved patient outcomes.

To read and listen to more of our conference coverage, click here.

Click here for more insights from Del Rosso, including the full interview with Dermatology Times on his presentation at Winter Clinical 2025.